Ma: Male, born in March 1974, with China nationality and no permanent residency abroad, holds a bachelor's degree and a doctor's degree in pharmacology of traditional Chinese medicine from China Pharmaceutical University. Mr. Ma has been engaged in new drug development and drug toxicology research for 20 years and has rich experience in new drug development. From July 65438 to July 2000, he worked in Tianjin Central Pharmaceutical Co., Ltd. as a pharmaceutical researcher. From June 2000 to July 2005, I worked in Guangdong Tianzhijiao Pharmaceutical Development Co., Ltd. as the manager of Pharmacology and Toxicology Department. From June 2005 to October 2005, I have been working in our company. I used to be a director of the company, and now I am the deputy general manager and director of the Drug Evaluation Center (GLP Center), in charge of preclinical research and development of new drugs, mainly engaged in pharmacopharmacology and new drug development. He is currently a member of the Safety Pharmacology Committee of Chinese Pharmacology Society, a member of the Drug Toxicology and Safety Evaluation Committee of China Toxicology Society, a member of the Chinese Medicine and Natural Medicine Committee of China Toxicology Society, a director of Guangdong Pharmacology Society, a deputy director of the Drug Screening and Evaluation Committee of Guangdong Pharmacology Society, a standing member of the Drug Toxicology Committee of Guangdong Pharmacology Society, and a director of the Engineering Technology Center for Active Ingredients of Chinese Medicine in Guangdong Province. Responsible for more than 30 drug research and development projects, obtained 3 production approvals, 5 clinical research approvals, published more than 30 academic articles, applied for nearly 20 patents, and presided over or participated in more than 0 national provincial and municipal fund projects/kloc-0.